Search results for "Autologou"

showing 10 items of 161 documents

Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.

2003

The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy. The median age of the patients was 57 years (range 22-67). In all, 268 patients received peripheral blood stem cells, and 47 patients received autologous bone marrow. After a median follow-up of 57 months (range 10-125), three cases of secondary AML (sAML) were observed, resulting in a cumulative incidence of 0.94%. One case of sAML developed 18 months after HDCT (FAB M3) The karyotype was trans…

OncologyTransplantation Conditioningmedicine.medical_treatmentAutologous stem-cell transplantationLeukemia Promyelocytic Acutehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMelphalanBone Marrow TransplantationLeukemia Radiation-InducedAcute leukemiaIncidenceCytarabineNeoplasms Second PrimaryHematologyMiddle AgedCombined Modality TherapyLeukemia MyeloidLymphatic MetastasisAcute DiseaseFemalemedicine.drugAdultmedicine.medical_specialtyPaclitaxelBreast NeoplasmsTransplantation AutologousLeukemia Myelomonocytic AcuteBreast cancerInternal medicinemedicineAdjuvant therapyHumansCyclophosphamideAgedEpirubicinTransplantationChemotherapyMitoxantronePeripheral Blood Stem Cell Transplantationbusiness.industryDaunorubicinmedicine.diseaseSurgeryRadiation therapyTransplantationDoxorubicinRadiotherapy AdjuvantMitoxantronebusinessThiotepaBone marrow transplantation
researchProduct

The role of stem cell transplantation in follicular lymphoma.

2017

With the introduction of novel treatments paradigms to if or when to use transplantation strategies for patients with follicular lymphoma have changed substantially. Autologous transplantation has been intensively evaluated as consolidation after first induction treatment with positive effects, however the introduction of Rituximab led to comparable improvements and HDT has been moved to relapse treatment. In this indication HDT was frequently use already at first relapse, but now is dominantly used in patients with a highrisk profile, e.g. failure of response, early or multiply relapse and/or signs of transformation. The ideal place for allogeneic transplantation is even harder to define, …

Oncologymedicine.medical_specialtyAllogeneic transplantationSide effectClinical BiochemistryFollicular lymphomaTransplantation Autologous03 medical and health sciences0302 clinical medicineInternal medicinemedicineAutologous transplantationHumansIn patientPrecision MedicineLymphoma Follicularbusiness.industryHematopoietic Stem Cell Transplantationmedicine.diseaseTransplantationOncology030220 oncology & carcinogenesisRituximabStem cellbusinessRituximab030215 immunologymedicine.drugBest practiceresearch. Clinical haematology
researchProduct

Immunotherapy of Metastasizing Renal Cell Carcinoma

1989

119 patients with stage-IV renal cell carcinoma were treated using immunotherapy with autologous tumor vaccine. The immunization was carried out at monthly intervals, the patients were restaged every

Oncologymedicine.medical_specialtyImmunizationRenal cell carcinomabusiness.industryUrologyInternal medicinemedicine.medical_treatmentmedicineImmunotherapymedicine.diseasebusinessAutologous tumorUrologia Internationalis
researchProduct

Transplantation in follicular lymphoma: not "yes or no" but "whom and when".

2013

After years of debate, the question as to what is the optimal use of transplantation strategies in indolent lymphoma remains controversial. In the July issue of Haematologica, a study was published by the EBMT Lymphoma Working Party that aims to define indications for hematopoietic stem cell

Oncologymedicine.medical_specialtyPathologybusiness.industryPatient SelectionFollicular lymphomaHematopoietic Stem Cell TransplantationHematopoietic stem cellEditorials and PerspectivesHematologymedicine.diseaseTransplantation AutologousLymphomaIndolent lymphomaTransplantationmedicine.anatomical_structureimmune system diseaseshemic and lymphatic diseasesInternal medicinemedicineHumansbusinessLymphoma FollicularHaematologica
researchProduct

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results f…

2021

Abstract Background: Treatment regimens including a proteasome inhibitor, immunomodulating agent and a monoclonal antibody (moAb) play an emerging role in the treatment of newly-diagnosed multiple myeloma (NDMM). This multicenter phase III trial of the German-speaking Myeloma Multicenter Group (GMMG HD6) investigated the addition of the anti-SLAMF7 moAb elotuzumab to lenalidomide / bortezomib / dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible NDMM. Patients and Methods: Patients were equally randomized into four treatment arms, stratified by International Staging System (ISS). Treatment consisted of four 21-da…

Oncologymedicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologyNewly diagnosedmedicine.diseaseBiochemistryInternal medicineMedicineAutologous transplantationElotuzumabbusinessMultiple myelomaBortezomib/dexamethasonemedicine.drugLenalidomideBlood
researchProduct

Tertiary hyperparathyroidism: a review

2021

Abstract: Tertiary hyperparathyroidism (HPT III) occurs when an excess of parathyroid hormone (PTH) is secreted by parathyroid glands, usually after longstanding secondary hyperparathyroidism. Some authorities reserve the term for secondary hyperparathyroidism that persists after successful renal transplantation. Long-standing chronic kidney disease (CKD) is associated with several metabolic disturbances that lead to increased secretion of PTH, including hyperphosphatemia, calcit-riol deficiency, and hypocalcaemia. Hyperphosphatemia has a direct stimulatory effect on the parathyroid gland cell resulting in nodular hyperplasia and increased PTH secretion. Prolonged hypocalcaemia also causes …

ParathyroidectomyHyperplasiametabolic disturbancesparathyroidec-tomyHypocalcemiaCalcimimeticstertiary hyperparathyroidismKidney TransplantationTransplantation AutologousHyperphosphatemiaParathyroid GlandsParathyroid HormoneHumansHyperparathyroidism SecondaryRenal Insufficiency Chronic
researchProduct

Prospective Study of Parathyroid Graft Function in Patients with Renal Hyperparathyroidism After Total Parathyroidectomy and Heterotopic Autotranspla…

1999

Evaluation of the value of gradients for intact parathyroid hormone after total parathyroidectomy and heterotopic autotransplantation for renal hyperparathyroidism.Prospective long-term follow-up study.Teaching hospital, Germany.A total of 115 patients operated on for renal hyperparathyroidism between 1 August 1987 to 15 August 1997.100/115 had total parathyroidectomy with autotransplantation.Analyses of serum calcium, alkaline phosphatase, and intact parathormone in serum 1, 4, 8, 12, 18 and 24 months postoperatively and annually thereafter. Parathormone gradients were calculated as the ratio of the parathormone concentrations in the antecubital venous blood of the grafted and the non-graf…

ParathyroidectomyParathyroidectomyHyperparathyroidismmedicine.medical_specialtyTransplantation Heterotopicbusiness.industrymedicine.medical_treatmentTotal parathyroidectomyMetabolic disorderVenous bloodmedicine.diseaseTransplantation AutologousAutotransplantationSurgeryParathyroid GlandsParathyroid HormonemedicineHumansAlkaline phosphataseHyperparathyroidism SecondarySurgeryProspective StudiesRenal InsufficiencyProspective cohort studybusinessThe European Journal of Surgery
researchProduct

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

2017

Abstract The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for …

PathologyNeoplasm ResidualInternational CooperationDiseaseReview ArticleBiochemistryEuropean LeukemiaNet0302 clinical medicineRisk Factorshemic and lymphatic diseasesCONVENTIONAL CARE REGIMENSDisease management (health)medicine.diagnostic_testACUTE MYELOGENOUS LEUKEMIAHematopoietic Stem Cell TransplantationDisease ManagementSINGLE CEBPA MUTATIONSHematology1ST COMPLETE REMISSIONHIGH-DOSE CYTARABINELeukemia Myeloid AcuteTreatment Outcome030220 oncology & carcinogenesisPractice Guidelines as TopicAdultmedicine.medical_specialtyConsensusImmunologyBUSULFAN PLUS CYCLOPHOSPHAMIDEMEDLINEMINIMAL RESIDUAL DISEASEAntineoplastic AgentsACUTE MYELOID-LEUKEMIAEnasidenibTransplantation AutologousDrug Administration ScheduleImmunophenotyping03 medical and health sciencesmedicineHumansGenetic TestingIntensive care medicineGenetic testingbusiness.industrySTEM-CELL TRANSPLANTATIONCell BiologyRANDOMIZED PHASE-IIIMinimal residual diseaseTransplantationbusinessSettore MED/15 - Malattie del Sangue030215 immunology
researchProduct

Adipose tissue sensitivity to radiation exposure

2008

1525-2191 (Electronic) Journal Article Research Support, Non-U.S. Gov't; Treatment of cancer using radiation can be significantly compromised by the development of severe acute and late damage to normal tissue. Treatments that either reduce the risk and severity of damage or that facilitate the healing of radiation injuries are being developed, including autologous adipose tissue grafts to repair tissue defects or involutional disorders that result from tumor resection. Adipose tissue is specialized in energy storage and contains different cell types, including preadipocytes, which could be used for autologous transplantation. It has long been considered a poorly proliferative connective ti…

Pathologymedicine.medical_specialtyCellular differentiationPopulationExperimental/metabolism/*pathologyAdipose tissueConnective tissueCell Proliferation/*radiation effectsBiologyPolymerase Chain ReactionPathology and Forensic MedicineMiceOxidative Stress/radiation effectsmedicineAdipocytesIn Situ Nick-End LabelingAutologous transplantationAnimalsStem Cells/metabolism/pathology/radiation effectsProgenitor celleducationRadiation InjuriesCell Proliferationeducation.field_of_studyStem CellsAdipocytes/cytology/metabolism/*radiation effectsCell DifferentiationTotal body irradiationFlow CytometryImmunohistochemistryAdipose Tissue/cytology/*radiation effectsOxidative StressRadiation Injuries ExperimentalCell Differentiation/*radiation effectsmedicine.anatomical_structurePhenotypeAdipose TissueStem cellRegular Articles
researchProduct

In vitro and in vivo investigations of osteogenic differentiation ability of dental pulp stem cells (DPSCs) and gingival mesenchymal stem cells (GMSC…

2020

Thanks to the use of human mesenchymal stem cells (hMSCs), smart biomaterials and active biomolecules, Regenerative Medicine (RM) and Bone Tissue Engineering (BTE) can restore structure and function of injured tissues. Among the different sources of hMSCs, the oro-facial hMSCs have promising in vitro and in vivo regeneration potential; in particular, dental pulp and gingiva are valuable sources of autologous hMSCs. The aim of this PhD thesis is testing the in vitro and in vivo bone regeneration ability of hMSCs isolated from dental pulp and inflamed gingiva of periodontally-compromised teeth, up to now considered biological waste tissues and discarded during surgical procedures, on two comm…

Periodontitis bone resorption oral MSCs DPSCs GMSCs waste biological tissues periodontally-compromised teeth FISIOGRAFT Bone Granular® Matriderm® autologous bone tissue regenerationSettore MED/28 - Malattie Odontostomatologiche
researchProduct